Pharmaceutical companies face a challenge when developing drugs that may be used to treat newborns, infants, and children due to the ethical concerns of including these groups in clinical trials. Modeling and simulation can accelerate the development of pediatric medicines.

### Background

Quetiapine is an atypical antipsychotic drug for the treatment of schizophrenia, bipolar disorder, major depressive disorder and generalized anxiety disorder. An immediate-release (IR) formulation of quetiapine was first approved by the FDA in 1997 and has been extensively studied in adults, children and adolescents. Regulatory approval for the extended-release (XR) formulation was granted for use in adults, with the requirement that pediatric studies must be carried out for children over the age of 12.

### Challenge

Various factors influence the bioavailability of different formulations including the release of the active ingredient, its dissolution and permeability across the gastrointestinal tract as well as intestinal metabolism. Furthermore, alterations in pharmacokinetics in children can be due to differences in absorption and transit rate, organ size, blood flow, tissue composition and metabolic capacity at various developmental stages. The challenge was to integrate the available in vitro ADME, physiochemical and clinical data into physiological-based pharmacokinetic (PBPK) models to predict the effects of age and formulation on the pharmacokinetics (PKs) of quetiapine in young subjects.

### Solution

Scientists at Simcyp (part of Certara) and AstraZeneca developed PBPK models that predicted, with reasonable accuracy, the effects of CYP3A4 inhibition and induction on the PK of quetiapine, the PK profile of quetiapine IR in both children and adults, and the PK profile of quetiapine XR in adults.
These validated models were then used to simulate relative exposure following XR formulation in adolescents (age 13-17) and children (age 10-12). In both groups, the predicted exposure to quetiapine XR followed a similar pattern to the IR formulation, with 300 mg XR once daily being comparable with 150 mg IR twice a day.\(^1\)

**Benefit**

The results of this study helped a major pharmaceutical company to determine dosing regimens for adolescents and older children using quetiapine XR formulations. This provides an example of how a “learn-and-confirm” approach can be applied for studying pediatric PKs which can be adapted to other medicines that have already received market approval as well as those that are currently in development.

**Impact**

As well as being a regulatory requirement, successfully developing a drug that can be safely used in the pediatric population can gain additional marketing exclusivity. This can be extremely lucrative, particularly for ‘blockbuster’ drugs where competition from generics is likely to be high. Furthermore, a new formulation for a pediatric indication for an “off-patent” drug can secure 10 years of market protection, offering further incentives for pharmaceutical companies to focus on developing medicines for children.

**References**


---

**About Certara**

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

For more information visit www.certara.com or email sales@certara.com.

© Copyright Certara 2016. All information presented derive from public source materials.